Orforglipron dosing & administration
First oral non-peptide GLP-1 receptor agonist for diabetes and obesity
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much Orforglipron do I take?
Oral: Taken by mouth as a capsule, tablet, or liquid.
Bioavailability Varies by compound — many peptides are largely broken down in the gut, so little reaches the blood intact; some small molecules absorb well.
Titration schedule
0.8 mg once daily
Frequency
Once daily, with or without food
Duration
At least 30 days
5.5 mg once daily
Frequency
Once daily, with or without food
Duration
Ongoing, reached after at least 30 days each on 0.8 mg and 2.5 mg
9–17.2 mg once daily
Frequency
Once daily, with or without food
Duration
Ongoing; each step after at least 30 days on the previous dose
Timing
Best time to take
Take Orforglipron at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
With food?
Orforglipron can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
If stacking
Orforglipron should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use Orforglipron?
Reconstitution
What you need
Injection
Route
Orforglipron is administered oral—no injection required
Best sites
Storage
Before reconstitution
Store FOUNDAYO tablets at room temperature, 20–25°C (68–77°F); brief excursions between 15°C and 30°C (59–86°F) are permitted. [7] Keep them in the original bottle, which comes with a desiccant. [7] Check the expiration date before use.
After reconstitution
Not applicable — FOUNDAYO is a film-coated tablet swallowed whole; there is nothing to reconstitute or mix. [7]
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: oral—rotate sites if applicable
Maintain a consistent schedule for optimal results with Orforglipron. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is Orforglipron safe?
Side effects
Commonly reported: Nausea, Constipation, Diarrhea, Vomiting
Less common: Heart Rate Increase
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Orforglipron
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Orforglipron should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Injectable GLP-1 Receptor Agonists — Redundant GLP-1R activation with no additional benefit and increased gastrointestinal adverse events
- DPP-4 Inhibitors — Overlapping incretin pathway stimulation provides minimal additional efficacy when combined with a direct GLP-1R agonist
- Sulfonylureas — Increased hypoglycemia risk from non-glucose-dependent insulin secretion combined with GLP-1R-mediated insulin release
Published research
What the studies show
Pratt E, Ma X, Liu R, et al. · 2023
Phase 1a study in 92 healthy adults: half-life was 24.6–35.3 hours after single doses and 48.1–67.5 hours after 4 weeks of daily dosing; body weight fell by up to 5.4 kg against 2.4 kg on placebo over 4 weeks. Most adverse events were gastrointestinal, and dosing was without water or food restrictions.
Pratt E, Ma X, Liu R, et al. · 2023
Research (2023) on orforglipron contributes important scientific knowledge about its biological and pharmacological properties.
Pillai AA, Sharma AM, Krayem H, et al. · 2025
Research (2025) on orforglipron contributes important scientific knowledge about its biological and pharmacological properties.
Hammad N, Ramadan AM, Nazmy A, et al. · 2026
Research (2026) demonstrates orforglipron's efficacy in clinical treatment and therapeutic applications.
Zhou J, Wang F, Li S, et al. · 2025
Research (2025) demonstrates orforglipron's efficacy in clinical treatment and therapeutic applications.
Lilly ATTAIN-1 / NEJM · 2025
Eli Lilly and Company / U.S. FDA (DailyMed) · 2026
Approved for long-term weight reduction in adults with obesity, or overweight with at least one weight-related condition. Boxed warning for thyroid C-cell tumours (orforglipron is not active in rodents and caused no rodent tumours); contraindicated with personal or family history of MTC or MEN 2, or serious hypersensitivity. Dosing: 0.8 mg once daily, with or without food, then 2.5 mg and 5.5 mg after at least 30 days each, optionally 9, 14.5 or 17.2 mg (maximum). In two 72-week phase 3 trials, weight fell 7.4%, 8.3% and 11.1% on 5.5, 9 and 17.2 mg vs 2.1% on placebo without diabetes, and 5.1%, 7.0% and 9.6% vs 2.5% with type 2 diabetes. Most common reactions: nausea (26-35% vs 10%), constipation, diarrhoea, vomiting, dyspepsia, abdominal pain. Absolute bioavailability 77%; half-life about 29-49 hours; metabolised mainly by CYP3A4.
U.S. Food and Drug Administration · 2026
NDA 220934 (Eli Lilly and Co): original approval 1 April 2026, a Type 1 new molecular entity; labelling supplement approved 4 August 2026.
Head to head
Orforglipron compared
Want the full picture?
The complete Orforglipron research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.